Navigation Links
Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
Date:1/24/2012

PHILADELPHIA, Jan. 24, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating clinical studies of its Symphony tCGM System in critical care patients. The company expects to complete and announce the results of the studies in the near term.

"We are very excited to initiate patient enrollment in our next studies of the Symphony system in the important hospital critical care setting," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "The goal of these trials is to demonstrate Symphony's performance in the large and emerging critical care market for non-invasive continuous glucose monitoring. We believe that Symphony addresses this unmet need, potentially improving patient outcomes."

Echo's clinical studies will enroll up to thirty (30) critical care patients and will compare data obtained from its Symphony tCGM System with the YSI 2300 STAT Plus Glucose Analyzer.  The studies are expected to collect more than 1,000 data pairs to be used in the analyses by taking frequent reference glucose measurements for 24 hours.  The data from the studies will be blinded to study subjects and study personnel. A comparison of the data relative to the blood glucose values will be used to assess the accuracy of Symphony.

About Continuous Glucose Monitoring in Critical Care

Hyperglycemia is common in critically ill patients, even in those that do not have a history of diabetes. Intensive insulin therapy and frequent glucose monitoring in critically ill patients has been proven in clinical studies to significantly reduce patient morbidity and mortality.  Intensive insulin therapy requires frequent, often hourly, nurse intervention to monitor blood glucose and adjust insulin administration to avoid hypoglycemia. The potential benefits of accurate continuous glucose monitoring in critical care are widely recognized.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including: the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems; the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems; Echo's ability to secure additional commercial partnering arrangements; risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems; the availability of substantial additional funding to support its research, development and product commercialization activities; and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Forms 10-Q, and its Current Reports on Forms 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215)717-4104                                                                    

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
2. Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
3. Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
4. Lightlake Therapeutics Inc. to Apply Companys Patented Technology in the Development of Premenstrual Syndrome Overeating Treatment
5. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
6. Orexigen Therapeutics to Present at the J.P. Morgan Healthcare Conference
7. Halo Therapeutics HT-100 Receives FDAs Orphan Designation for Duchenne Muscular Dystrophy
8. Echo Therapeutics Announces $3.6 Million Warrant Exercises
9. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
10. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
11. AuraSense Therapeutics Secures Series B Equity Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Italia, March 1, 2017 El mismo sistema se mostrará en ... Reading ... The open MRI scanner - MROpen engineered ... ... en el Reino Unido y la primera en Gales. El escáner se localizará en el ...
(Date:2/28/2017)... -- Mechanical Ventilators Market: Scope of the Study ... This report provides forecast and analysis of the ... It provides historical data of 2015 along with forecast ... Mn) and volume (units). The report also includes macroeconomic ... globally. It includes drivers and restraints of the mechanical ...
(Date:2/28/2017)... 28, 2017 Persistence Market Research tables ... management market in a new publication named, "Dysphagia ... As the name suggests, we have forecasted the ... and on the basis of the various market ... the opportunities available to all the companies operating ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... ... One of the most popular shows on television, NBC’s This is Us, ended it’s ... to life after suffering cardiac arrest on Christmas Eve. Viewers were relieved to ... to marry his best girl. In reality only 10% of out-of-Hospital cardiac arrest ...
(Date:3/1/2017)... ... ... (HPE) today announced its VelociRaptor 600 upgrade for the 2017 Ford Raptor truck. The ... bhp and 510 lb-ft of torque to 605 bhp and 622 lb-ft. of torque. ... running down the ¼ mile in just 12.9 seconds at 110 mph. , “Our last ...
(Date:3/1/2017)... ... , ... The Industrial Designers Society of America (IDSA) is marking National ... of industrial design (ID) and relaunching "What Is ID?" —one of the most ... parents; and the greater public. , Share details and photos of National ID Day ...
(Date:3/1/2017)... HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... cryoablation for the treatment of early stage breast cancer and where it fits in ... Genes & The Choices We Make .” The event brings together leading cancer and ...
(Date:3/1/2017)... ... , ... NYC based Integrated practice Living Well Medical, a long time leader ... Orthopaedic Surgeon Dr. Donald E. Heitman. Dr. Heitman is a native of ... of Science degree in biology. He then obtained his medical degree from New York ...
Breaking Medicine News(10 mins):